Dynavax Says Phase 3 Data on HEPLISAV for Adults Age 40-70 Published in VACCINE

Dynavax Technologies Corporation (NASDAQ: DVAX ) announced today that immunogenicity and safety results of two Phase 3 trials (HBV-16 and HBV-17) of HEPLISAV(TM) investigational hepatitis B vaccine were published in the journal VACCINE accompanied by a Commentary from Drs. Stanley Plotkin and William Schaffner. The Commentary emphasizes the effect of 1018, the novel adjuvant contained